Kristie L. Kahl

Articles

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

April 11th 2021

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Olaparib/Cediranib Fails to Significantly Improve PFS Over Cediranib Alone in Advanced Endometrial Cancer

March 22nd 2021

Although the combination of olaparib and cediranib showcased modest efficacy over cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer, the difference was not statistically significant.

PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer

February 12th 2021

February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8th 2021

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

Pembrolizumab Continues to Improve Survival in PD-L1–Positive Advanced NSCLC

January 28th 2021

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Behavioral Interventions Reduce Depressive Symptoms in Young Breast Cancer Survivors

December 10th 2020

December 10, 2020 - Mindfulness meditation and survivorship education classes reduced depressive symptoms in younger women treated for breast cancer.

Women Who Undergo Mastectomy with Reconstruction At Higher Risk for Chronic Controlled Substance Use

December 9th 2020

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma

December 7th 2020

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC

September 21st 2020

Treatment with cabozantinib in combination with atezolizumab demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma.